Literature DB >> 32057899

The regulation of TFEB in lipid homeostasis of non-alcoholic fatty liver disease: Molecular mechanism and promising therapeutic targets.

Shenglan Yu1, Zhengtao Wang2, Lili Ding3, Li Yang4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD), which is characterized by disruption of lipid homeostasis, has been the leading cause of chronic liver disease worldwide. However, currently there is no effective therapy for NAFLD. Consequently, it is extremely urgent to explore the specific and effective target functioned as lipids regulator during the pathological process of NAFLD for the drug development. Transcription factor EB (TFEB) plays a crucial role in the regulation of lipid homeostasis through linking autophagy to energy metabolism at the transcriptional level. In this review, we summarize the currently available information regarding the mediation of TFEB in lipid metabolism during the pathological process of NAFLD, and the specific regulatory mechanism of TFEB activity. We further recapitulate TFEB as a promising therapeutic target for NAFLD, primarily through the regulation of lipid homeostasis, energy metabolism as well as immune defense. A better understanding of these key issues will be helpful to promote the development of therapeutic agents which specifically target TFEB to halt or reverse the pathological progression of NAFLD.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autophagy; Lipid metabolism; Lysosome function; NAFLD; Transcription factor EB

Year:  2020        PMID: 32057899     DOI: 10.1016/j.lfs.2020.117418

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Transcription factor EB inhibits non-alcoholic fatty liver disease through fibroblast growth factor 21.

Authors:  Qi Gong; Xie Zhang; Yixuan Sun; Jixiang Shen; Xiuping Li; Chao Xue; Zhihua Liu
Journal:  J Mol Med (Berl)       Date:  2022-09-14       Impact factor: 5.606

Review 2.  Role of TFEB in Autophagy and the Pathogenesis of Liver Diseases.

Authors:  Shengmin Yan
Journal:  Biomolecules       Date:  2022-05-06

Review 3.  The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease.

Authors:  Aldo Grefhorst; Ivo P van de Peppel; Lars E Larsen; Johan W Jonker; Adriaan G Holleboom
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-01       Impact factor: 5.555

Review 4.  The Oncogene Transcription Factor EB Regulates Vascular Functions.

Authors:  Gabriella Doronzo; Elena Astanina; Federico Bussolino
Journal:  Front Physiol       Date:  2021-04-12       Impact factor: 4.566

5.  Aurantio-Obtusin Attenuates Non-Alcoholic Fatty Liver Disease Through AMPK-Mediated Autophagy and Fatty Acid Oxidation Pathways.

Authors:  Fei Zhou; Mingning Ding; Yiqing Gu; Guifang Fan; Chuanyang Liu; Yijie Li; Rong Sun; Jianzhi Wu; Jianchao Li; Xiaoyong Xue; Hongjuan Li; Xiaojiaoyang Li
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810

Review 6.  The Regulation of MiTF/TFE Transcription Factors Across Model Organisms: from Brain Physiology to Implication for Neurodegeneration.

Authors:  Francesco Agostini; Rossella Agostinis; Diego L Medina; Marco Bisaglia; Elisa Greggio; Nicoletta Plotegher
Journal:  Mol Neurobiol       Date:  2022-06-04       Impact factor: 5.682

7.  The TFEB-TGIF1 axis regulates EMT in mouse epicardial cells.

Authors:  Elena Astanina; Gabriella Doronzo; Davide Corà; Francesco Neri; Salvatore Oliviero; Tullio Genova; Federico Mussano; Emanuele Middonti; Edoardo Vallariello; Chiara Cencioni; Donatella Valdembri; Guido Serini; Federica Limana; Eleonora Foglio; Andrea Ballabio; Federico Bussolino
Journal:  Nat Commun       Date:  2022-09-03       Impact factor: 17.694

Review 8.  Multifaceted activities of transcription factor EB in cancer onset and progression.

Authors:  Elena Astanina; Federico Bussolino; Gabriella Doronzo
Journal:  Mol Oncol       Date:  2020-12-23       Impact factor: 7.449

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.